We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current MLTX market cap is 3.12B. The company's latest EPS is USD -0.6898 and P/E is -70.76.
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | ||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -13.19M | -12.98M | -15.03M | -19.82M | -30.58M |
| Net Income | -12.35M | -11.62M | -7.89M | -13.98M | -23.97M |
| Year End 31 December 2023 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 |
| Operating Income | -106k | -4.57M | -65.06M | -54.12M |
| Net Income | -91k | -4.54M | -64.51M | -44.08M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | ||
| Total Assets | 506.62M | 500.22M | 526.54M | 564.12M | 544.88M |
| Total Liabilities | 7.51M | 10.58M | 13.05M | 11.73M | 14.85M |
| Total Equity | 499.11M | 489.64M | 513.49M | 552.39M | 530.03M |
| Year End 31 December 2023 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 116.63M | 115.84M | 76.84M | 526.54M |
| Total Liabilities | 4.15M | 7.9M | 8.08M | 13.05M |
| Total Equity | 5M | -7.06M | 68.77M | 513.49M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | ||
| Operating | -21.18M | -30.43M | -42.78M | -14.95M | -42.84M |
| Investing | 32.33M | -142.05M | -25.19M | -28.8M | -116.55M |
| Financing | 451.29M | 451.29M | 479.7M | 50.98M | 50.98M |
| Year End 31 December 2023 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -317k | -611k | -55.89M | -42.78M |
| Investing | -115M | N/A | -32.34M | -25.19M |
| Financing | 116.65M | -58k | 119.69M | 479.7M |
| Market Cap | 3.12B |
| Price to Earnings Ratio | -70.76 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 6.91 |
| Price to Book Ratio | 6.07 |
| Dividend Yield | - |
| Shares Outstanding | 63.91M |
| Average Volume (1 week) | 193.07k |
| Average Volume (1 Month) | 220.88k |
| 52 Week Change | 30.21% |
| 52 Week High | 64.98 |
| 52 Week Low | 37.345 |
| Spread (Intraday) | 28 (42.42%) |
| Company Name | MoonLake Immunotherapeutics |
| Address |
p.o. box 309 grand cayman 1104 |
| Website | https://moonlaketx.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
